Reaction

Granulocyte Count Decreased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,759 reports · 62 co-occurring drugs

As of the last recalculation, Granulocyte Count Decreased appears in 1,759 FAERS reports alongside 62 co-occurring drug terms. The strongest observed disproportionality signal is DEXTROSE MONOHYDRATE (PRR 109.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Dextrose Monohydrate	116	109.9	110.8
Dextrose	112	107.4	108.3
Sodium Chloride Tablet	297	57.3	57.5
Sodium Chloride Tablets	297	57.3	57.5
Sodium Chloride	298	53.5	53.7
Azacitidine For	67	45.3	45.4
Irinotecan Hydrochloride	42	39.6	39.7
Cetuximab	98	39.1	39.3
Dexamethasone Sodium Phosphate	28	33.1	33.2
Cytarabine	151	32.4	32.5
Leucovorin Calcium	47	29.9	29.9
Azacitidine	69	28.6	28.7
Venetoclax	113	23.1	23.2
Polatuzumab Vedotin	17	20.8	20.8
Pertuzumab	45	20.1	20.1
Paclitaxel (Aibumin-Bound)	127	19.6	19.7
Trastuzumab	103	18.8	18.8
Mesna Injection	12	17.3	17.3
Mesna	12	17.0	17.0
Paclitaxel	130	16.7	16.7
Cyclophosphamide Injection, Solution	219	16.6	16.6
Cyclophosphamide	219	16.6	16.6
Cyclophosphamide For Injection	219	16.6	16.6
Oxaliplatin	97	16.3	16.3
Docetaxel Anhydrous	88	16.2	16.2
Docetaxel	88	16.2	16.2
Fluorouracil Cream, 0.5%	98	16.0	16.1
Fluorouracil	98	15.8	15.8
Cisplatin	90	14.3	14.3
Bendamustine Hydrochloride	14	13.9	14.0
Doxorubicin Hydrochloride	33	12.2	12.2
Carboplatin	122	12.1	12.1
Vincristine Sulfate	28	11.5	11.5
Etoposide	64	10.7	10.7
Pemetrexed Disodium	32	10.1	10.1
Bendamustine Hcl	13	10.0	10.0
Gemcitabine Hydrochloride	43	9.8	9.8
Brentuximab Vedotin	8	9.3	9.3
Bevacizumab	90	9.0	9.0
Letrozole Tablets	34	8.5	8.5
Melphalan	15	7.9	7.9
Doxorubicin	57	7.8	7.8
Ifosfamide	14	7.8	7.8
Capecitabine	58	7.7	7.7
Daratumumab	25	7.5	7.5
Letrozole	38	7.4	7.4
Obinutuzumab	10	7.2	7.2
Ribociclib	19	7.2	7.2
Palbociclib	53	6.7	6.8
Meropenem	18	6.7	6.7
Lapatinib	8	6.1	6.1
Carfilzomib	14	5.9	5.9
Pegaspargase	6	5.8	5.8
Linezolid	14	5.6	5.6
Selinexor	4	5.5	5.5
Abemaciclib	8	4.8	4.8
Gemcitabine	15	4.5	4.5
Fam-Trastuzumab Deruxtecan-Nxki	3	3.5	3.5
Peginterferon Alfa-2A	16	3.5	3.5
Olaparib	5	2.8	2.8
Osimertinib	7	2.6	2.6
Pomalidomide	19	2.2	2.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.